Cargando…

Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease

Background: Prior studies report that monoamine oxidases inhibitors (MAO-I) when used as an adjunct to levodopa ameliorate motor symptoms in Parkinson’s disease (PD), but this was not tested in relation to cognitive or psychiatric measures. Objective: Here, we tested the effects of MAO-I as an adjun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krishna, Rakhee, Ali, Manal, Moustafa, Ahmed A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111079/ https://www.ncbi.nlm.nih.gov/pubmed/25120478 http://dx.doi.org/10.3389/fnagi.2014.00180

Ejemplares similares

Levodopa Enhances Reward Learning but Impairs Reversal Learning in Parkinson's Disease Patients
por: Moustafa, Ahmed A.
Publicado: (2011)

Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis
por: Wang, Yan, et al.
Publicado: (2021)

MAO-inhibitors in Parkinson's Disease
por: Riederer, Peter, et al.
Publicado: (2011)

Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors
por: Binde, Caroline D., et al.
Publicado: (2021)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
por: Finberg, John P. M., et al.
Publicado: (2016)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
por: Jost, Wolfgang H.
Publicado: (2022)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
por: Teo, Kay Cheong, et al.
Publicado: (2013)

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
por: Giladi, Nir, et al.
Publicado: (2016)

Differential Influence of Levodopa on Reward-Based Learning in Parkinson's Disease
por: Graef, Susanne, et al.
Publicado: (2010)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Parkinson's Disease: General Features, Effects of Levodopa Treatment and Future Directions
por: Freire, Marco Aurélio M., et al.
Publicado: (2010)

Levodopa-Induced Changes in Electromyographic Patterns in Patients with Advanced Parkinson’s Disease
por: Ruonala, Verneri, et al.
Publicado: (2018)

Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson’s Disease
por: Carvalho, Miguel M., et al.
Publicado: (2017)

Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson’s Disease
por: Song, Tianbin, et al.
Publicado: (2021)

Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs
por: Hagenow, Jens, et al.
Publicado: (2020)

Effect of Acute Levodopa Up-Titration on Blood Pressure in Patients With Early Stage Parkinson’s Disease: Results of a Levodopa Challenge Test
por: He, Xiaoqin, et al.
Publicado: (2022)

Morphologic brain network predicts levodopa responsiveness in Parkinson disease
por: Xie, Yongsheng, et al.
Publicado: (2023)

Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson’s Disease
por: Fabbri, Margherita, et al.
Publicado: (2017)

Brain-Region Specific Metabolic Abnormalities in Parkinson’s Disease and Levodopa-Induced Dyskinesia
por: Yang, Changwei, et al.
Publicado: (2020)

A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease
por: Muddapu, Vignayanandam Ravindernath-Jayashree, et al.
Publicado: (2022)

Comparison of Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa and Levodopa/COMT Inhibitor
por: Lee, Phil Hyu, et al.
Publicado: (2011)

Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson’s Disease
por: Perez-Pardo, Paula, et al.
Publicado: (2018)

Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease
por: Pieterman, Marcus, et al.
Publicado: (2018)

Pallidal Structural Changes Related to Levodopa-induced Dyskinesia in Parkinson's Disease
por: Youn, Jinyoung, et al.
Publicado: (2022)

Effects of levodopa on gut bacterial antibiotic resistance in Parkinson’s disease rat
por: Sheng, Shuo, et al.
Publicado: (2023)

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
por: Finberg, John P.M.
Publicado: (2010)

Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease
por: Duarte, Pablo, et al.
Publicado: (2022)

Levodopa Changes Functional Connectivity Patterns in Subregions of the Primary Motor Cortex in Patients With Parkinson’s Disease
por: Shen, Yang, et al.
Publicado: (2020)

Alterations of PAC-based resting state networks in Parkinson’s disease are partially alleviated by levodopa medication
por: Mertiens, Sean, et al.
Publicado: (2023)

Computationally Assisted Lead Optimization of Novel Potent and Selective MAO-B Inhibitors
por: Gogineni, Vedanjali, et al.
Publicado: (2021)

Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
por: Ramachandra, Vagdevi Hangarakatte, et al.
Publicado: (2022)

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson’s Disease
por: Nam, Min-Ho, et al.
Publicado: (2021)

Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review
por: Tsuboi, Takashi, et al.
Publicado: (2022)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2017)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
por: Regensburger, Martin, et al.
Publicado: (2023)

MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
por: Mallajosyula, Jyothi K., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_289mftekqcr3b628gms3n0hk70